Table 5. Summary of one-way sensitivity analysis outcomes for Oncotype DX testing versus standard care.
| Quality-adjusted life expectancy (QALYs) | Direct costs (EUR) | ICER*/Outcomes | |||||
|---|---|---|---|---|---|---|---|
| Oncotype DX | Standard care | Difference | Oncotype DX | Standard care | Difference | ||
| Base case | 11.32 | 11.16 | 0.17 | 11,489.81 | 11,137.36 | +352.45 | 2,134.36 |
| Time horizon 10 years | 6.27 | 6.22 | 0.05 | 8,407.83 | 7,677.39 | +730.44 | 14,772.57 |
| Time horizon 20 years | 9.79 | 9.67 | 0.12 | 10,589.40 | 10,171.99 | +417.41 | 3,476.99 |
| Time horizon 40 years | 11.58 | 11.41 | 0.17 | 11,636.39 | 11,287.70 | +348.69 | 2,003.20 |
| Discount rate 0% | 17.44 | 17.14 | 0.30 | 15,228.66 | 15,355.73 | -127.07 | DOMINANT |
| Discount rate 8% | 8.12 | 8.02 | 0.10 | 9,509.94 | 8,870.69 | +639.25 | 6,268.62 |
| Chemotherapy costs UL | 11.32 | 11.16 | 0.17 | 11,617.57 | 11,411.48 | +206.09 | 1,248.04 |
| Chemotherapy costs LL | 11.32 | 11.16 | 0.17 | 11,362.01 | 10,863.14 | +498.87 | 3,021.02 |
| Recurrence costs UL | 11.32 | 11.16 | 0.17 | 29,210.95 | 32,201.15 | -2,990.20 | DOMINANT |
| Recurrence costs LL | 11.32 | 11.16 | 0.17 | 7,999.83 | 6,989.08 | +1,010.75 | 6,120.87 |
| Relative risk of recurrence UL | 11.44 | 11.24 | 0.21 | 10,285.62 | 10,352.64 | -67.02 | DOMINANT |
| Relative risk of recurrence LL | 11.21 | 11.09 | 0.13 | 12,537.98 | 11,820.41 | +717.57 | 5,651.85 |
| Net change in chemotherapy use UL in low RS group | 11.32 | 11.16 | 0.17 | 11,376.21 | 11,137.36 | +238.84 | 1,435.46 |
| Net change in chemotherapy use LL in low RS group | 11.32 | 11.16 | 0.16 | 11,836.95 | 11,137.36 | +699.59 | 4,337.26 |
| Net change in chemotherapy use UL in intermediate RS group | 11.32 | 11.16 | 0.17 | 11,371.16 | 11,137.36 | +233.79 | 1,404.67 |
| Net change in chemotherapy use LL in intermediate RS group | 11.32 | 11.16 | 0.16 | 11,607.84 | 11,137.36 | +470.48 | 2,871.70 |
| Net change in chemotherapy use UL in high risk group | 11.36 | 11.16 | 0.20 | 11,248.41 | 11,137.36 | +111.04 | 551.70 |
| Net change in chemotherapy use LL in high risk group | 11.29 | 11.16 | 0.13 | 11,731.22 | 11,137.36 | +593.86 | 4,604.02 |
| 10 year risk of recurrence UL | 11.27 | 11.08 | 0.19 | 11,928.15 | 11,740.32 | +187.83 | 992.25 |
| 10-year risk of recurrence LL | 11.37 | 11.23 | 0.14 | 11,030.52 | 10,489.27 | +541.45 | 3,872.44 |
| Survival post recurrence UL | 11.20 | 11.03 | 0.17 | 12,720.28 | 12,367.83 | +352.45 | 2,134.54 |
| Survival post recurrence LL | 11.45 | 11.29 | 0.17 | 10,187.78 | 9,835.33 | +352.45 | 2,134.18 |
QALY, quality-adjusted life year; EUR, 2013 Euros; ICER, incremental cost-effectiveness ratio
* ICERs are presented in EUR per QALY gained; RS, Recurrence Score.